UMR85, Unité de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, Nouzilly, France.
Biol Reprod. 2011 Feb;84(2):351-62. doi: 10.1095/biolreprod.110.087023. Epub 2010 Oct 27.
Metformin is an insulin sensitizer molecule used for the treatment of infertility in women with polycystic ovary syndrome and insulin resistance. It modulates the reproductive axis, affecting the release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH). However, metformin's mechanism of action in pituitary gonadotropin-secreting cells remains unclear. Adenosine 5' monophosphate-activated protein kinase (PRKA) is involved in metformin action in various cell types. Here, we investigated the effects of metformin on gonadotropin secretion in response to activin and GnRH in primary rat pituitary cells (PRP), and studied PRKA in rat pituitary. In PRP, metformin (10 mM) reduced LH and follicle-stimulating hormone (FSH) secretion induced by GnRH (10(-8) M, 3 h), FSH secretion, and mRNA FSHbeta subunit expression induced by activin (10(-8) M, 12 or 24 h). The different subunits of PRKA are expressed in pituitary. In particular, PRKAA1 is detected mainly in gonadotrophs and thyrotrophs, is less abundant in lactotrophs and somatotrophs, and is undetectable in corticotrophs. In PRP, metformin increased phosphorylation of both PRKA and acetyl-CoA carboxylase. Metformin decreased activin-induced SMAD2 phosphorylation and GnRH-induced mitogen-activated protein kinase (MAPK) 3/1 (ERK1/2) phosphorylation. The PRKA inhibitor compound C abolished the effects of metformin on gonadotropin release induced by GnRH and on FSH secretion and Fshb mRNA induced by activin. The adenovirus-mediated production of dominant negative PRKA abolished the effects of metformin on the FSHbeta subunit mRNA and SMAD2 phosphorylation induced by activin and on the MAPK3/1 phosphorylation induced by GnRH. Thus, in rat pituitary cells, metformin decreases gonadotropin secretion and MAPK3/1 phosphorylation induced by GnRH and FSH release, FSHbeta subunit expression, and SMAD2 phosphorylation induced by activin through PRKA activation.
二甲双胍是一种胰岛素增敏剂分子,用于治疗多囊卵巢综合征和胰岛素抵抗的女性不孕。它调节生殖轴,影响促性腺激素释放激素(GnRH)和黄体生成素(LH)的释放。然而,二甲双胍在垂体促性腺激素分泌细胞中的作用机制尚不清楚。腺苷 5'一磷酸激活蛋白激酶(PRKA)参与了二甲双胍在各种细胞类型中的作用。在这里,我们研究了二甲双胍对原代大鼠垂体细胞(PRP)中促性腺激素分泌的影响,以及在大鼠垂体中 PRKA 的作用。在 PRP 中,二甲双胍(10mM)降低了 GnRH(10-8M,3 小时)诱导的 LH 和卵泡刺激素(FSH)分泌、FSH 分泌和激活素(10-8M,12 或 24 小时)诱导的 FSHβ亚基 mRNA 表达。PRKA 的不同亚基在垂体中表达。特别是,PRKAA1 主要在促性腺激素细胞和甲状腺细胞中检测到,在催乳素细胞和生长激素细胞中含量较少,在促肾上腺皮质激素细胞中检测不到。在 PRP 中,二甲双胍增加了 PRKA 和乙酰辅酶 A 羧化酶的磷酸化。二甲双胍降低了激活素诱导的 SMAD2 磷酸化和 GnRH 诱导的丝裂原活化蛋白激酶(MAPK)3/1(ERK1/2)磷酸化。PRKA 抑制剂化合物 C 消除了二甲双胍对 GnRH 诱导的促性腺激素释放和激活素诱导的 FSH 分泌和 Fshb mRNA 的作用。腺病毒介导的显性负 PRKA 的产生消除了二甲双胍对激活素诱导的 FSHβ亚基 mRNA 和 SMAD2 磷酸化以及 GnRH 诱导的 MAPK3/1 磷酸化的作用。因此,在大鼠垂体细胞中,二甲双胍通过激活 PRKA 降低 GnRH 和激活素诱导的促性腺激素分泌和 MAPK3/1 磷酸化、FSH 释放、FSHβ亚基表达和 SMAD2 磷酸化。